» Articles » PMID: 37549238

MALAT1 Regulates Network of MicroRNA-15a/16-VEGFA to Promote Tumorigenesis and Angiogenesis in Multiple Myeloma

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2023 Aug 7
PMID 37549238
Authors
Affiliations
Soon will be listed here.
Abstract

MALAT1 is one of the most hopeful members implicated in angiogenesis in a variety of non-malignant diseases. In multiple myeloma (MM), MALAT1 is recognized as the most highly expressed long non-coding RNA. However, the functional roles of MALAT1 in angiogenesis and the responsible mechanisms have not yet been explored. Herein, we discovered a novel regulatory network dependent on MALAT1 in relation to MM tumorigenesis and angiogenesis. We observed that MALAT1 was upregulated in MM and significantly associated with poor overall survival. MALAT1 knockdown suppressed MM cell proliferation and promoted apoptosis, while restricting endothelial cells angiogenesis. Moreover, MALAT1 directly targeted microRNA-15a/16, and microRNA-15a/16 suppression partly reverted the effects of MALAT1 deletion on MM cells in vitro as well as tumor growth and angiogenesis in vivo. In addition, further study indicated that MALAT1 functioned as a competing endogenous RNA for microRNA-15a/16 to regulate vascular endothelial growth factor A (VEGFA) expression. Our results suggest that MALAT1 plays an important role in the regulatory axis of microRNA-15a/16-VEGFA to promote tumorigenicity and angiogenesis in MM. Consequently, MALAT1 could serve as a novel promising biomarker and a potential antiangiogenic target against MM.

Citing Articles

LncRNA-MALAT1 promotes triple-negative breast cancer progression and function as ceRNA to target REEP5 by sponging miR-106a-5p.

Yang Q, Fu Y, Feng W, Mao J, Xu N, Liu Q Eur J Med Res. 2025; 30(1):159.

PMID: 40059235 PMC: 11892299. DOI: 10.1186/s40001-025-02420-x.


Exosomal lncRNAs as diagnostic and therapeutic targets in multiple myeloma.

Yan H, Jiang N, Li X, Lin C, Wang F, Zhang J Front Oncol. 2025; 14:1522491.

PMID: 39886670 PMC: 11779718. DOI: 10.3389/fonc.2024.1522491.


LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy.

Alkhathami A, Pallathadka H, Shah S, Ganesan S, Sharma A, Devi S Med Oncol. 2024; 42(1):28.

PMID: 39671022 DOI: 10.1007/s12032-024-02577-1.


Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy.

Huang P, Wen F, Li Q Front Pharmacol. 2024; 15:1432490.

PMID: 39119602 PMC: 11306149. DOI: 10.3389/fphar.2024.1432490.


Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy.

Al-Hawary S, Jasim S, Altalbawy F, Hjazi A, Jyothi S, Kumar A Med Oncol. 2024; 41(7):171.

PMID: 38849654 DOI: 10.1007/s12032-024-02392-8.